↓ Skip to main content

Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review

Overview of attention for article published in Clinical Epigenetics, March 2018
Altmetric Badge


9 Dimensions

Readers on

24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review
Published in
Clinical Epigenetics, March 2018
DOI 10.1186/s13148-018-0461-8
Pubmed ID

Muriel X. G. Draht, Danny Goudkade, Alexander Koch, Heike I. Grabsch, Matty P. Weijenberg, Manon van Engeland, Veerle Melotte, Kim M. Smits


Biomarkers that can predict the prognosis of colorectal cancer (CRC) patients and that can stratify high-risk early stage patients from low-risk early stage patients are urgently needed for better management of CRC. During the last decades, a large variety of prognostic DNA methylation markers has been published in the literature. However, to date, none of these markers are used in clinical practice. To obtain an overview of the number of published prognostic methylation markers for CRC, the number of markers that was validated independently, and the current level of evidence (LoE), we conducted a systematic review of PubMed, EMBASE, and MEDLINE. In addition, we scored studies based on the REMARK guidelines that were established in order to attain more transparency and complete reporting of prognostic biomarker studies. Eighty-three studies reporting on 123 methylation markers fulfilled the study entry criteria and were scored according to REMARK. Sixty-three studies investigated single methylation markers, whereas 20 studies reported combinations of methylation markers. We observed substantial variation regarding the reporting of sample sizes and patient characteristics, statistical analyses, and methodology. The median (range) REMARK score for the studies was 10.7 points (4.5 to 17.5) out of a maximum of 20 possible points. The median REMARK score was lower in studies, which reported a p value below 0.05 versus those, which did not (p = 0.005). A borderline statistically significant association was observed between the reported p value of the survival analysis and the size of the study population (p = 0.051). Only 23 out of 123 markers (17%) were investigated in two or more study series. For 12 markers, and two multimarker panels, consistent results were reported in two or more study series. For four markers, the current LoE is level II, for all other markers, the LoE is lower. This systematic review reflects that adequate reporting according to REMARK and validation of prognostic methylation markers is absent in the majority of CRC methylation marker studies. However, this systematic review provides a comprehensive overview of published prognostic methylation markers for CRC and highlights the most promising markers that have been published in the last two decades.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 21%
Other 3 13%
Researcher 2 8%
Lecturer 2 8%
Professor 1 4%
Other 4 17%
Unknown 7 29%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 25%
Medicine and Dentistry 5 21%
Agricultural and Biological Sciences 3 13%
Philosophy 1 4%
Nursing and Health Professions 1 4%
Other 2 8%
Unknown 6 25%